CIPN manifests as a constellation of sensory and motor impairments, including numbness, burning sensations, tingling, and muscle weakness that predominantly affect the feet. These symptoms often develop insidiously during or after chemotherapy, dramatically reducing patient quality of life. The underlying pathophysiology involves the neurotoxic effects of chemotherapy agents that damage peripheral nerves, especially in distal limbs where nerves are longest and most vulnerable. This damage disrupts normal nerve signaling, leading to the characteristic “pins and needles” feeling and loss of proprioception. Importantly, these neurological deficits can persist indefinitely, highlighting the critical need for early detection and management.

The University of South Australia conducted a comprehensive analysis of 3,292 colorectal cancer patients, among whom 82% received Oxaliplatin-based chemotherapy. Colorectal cancer represents a significant cohort given the widespread use of neurotoxic chemotherapy in its management. Despite the well-documented risk of CIPN associated with Oxaliplatin, the study revealed a startling statistic: only a minority of these patients engaged podiatry services within five years post-treatment. This lack of engagement suggests a profound disconnect between the recognition of CIPN symptoms and the integration of foot care into cancer survivorship plans.

Podiatrists possess specialized skills in managing lower limb disorders and are uniquely positioned to address the multifaceted challenges posed by CIPN. Their expertise encompasses assessment, prevention, and treatment strategies aimed at preserving neuromuscular function, preventing falls, and minimizing foot trauma. Early podiatric intervention can contribute to fall prevention—a critical factor given that CIPN-related balance impairments significantly heighten fall risk. Moreover, effective podiatric care can reduce the incidence of ulcerations and infections, which, if left untreated, may escalate to amputations. These complications underscore the potential life-altering consequences of neglecting foot health in chemotherapy patients.

Current oncology protocols often overlook podiatric involvement, focusing primarily on cancer control while underappreciating long-term functional impairments. This study highlights the urgent necessity for oncology care teams to integrate routine podiatric evaluations into survivorship programs. By routinely screening for CIPN symptoms and referring patients early to podiatrists, clinicians could enhance patient outcomes, reduce morbidity, and improve adherence to chemotherapy regimens by mitigating symptom severity. Indeed, severe CIPN symptoms sometimes prompt patients to discontinue treatment prematurely, adversely impacting cancer prognosis.

The absence of national guidelines specific to CIPN prevention and management in Australia exacerbates the challenge of coordinated care. Presently, the solitary published clinical pathway for CIPN management does not incorporate podiatry services, signifying a critical oversight in multidisciplinary care frameworks. To bridge this gap, the UniSA research team, with consensus from Australian podiatry professionals, has developed clinical recommendations emphasizing podiatry’s essential role. These guidelines advocate for early assessment and ongoing management to combat CIPN symptoms proactively, though awareness and implementation of these protocols remain limited.

Understanding the neurobiological mechanisms behind CIPN is pivotal in developing effective care strategies. Neurotoxicity induced by chemotherapy agents leads to axonal degeneration and mitochondrial dysfunction in sensory neurons, impairing nerve conduction velocity and causing debilitating sensory deficits. The resultant proprioceptive loss impairs patients’ ability to maintain balance, increasing susceptibility to falls and subsequent injuries. Podiatric interventions aimed at strengthening foot musculature, improving proprioceptive feedback, and providing protective orthotics can counterbalance these deficits, thereby safeguarding patient mobility and independence.

The study emphasizes that podiatry’s role transcends symptom relief, encompassing vital preventative care that reduces downstream complications. Considering that novel pharmacological agents to prevent or reverse CIPN are currently unavailable, supportive care through podiatry becomes indispensable. Preventing ulcerations and infections in the neuropathic foot can significantly diminish hospitalizations and improve survivorship quality, especially among aging cancer populations with comorbidities such as diabetes.

Education forms another cornerstone for addressing this silent crisis. Both patients and oncology clinicians often harbor limited knowledge regarding the benefits of podiatric care in CIPN management. Enhancing awareness through targeted education campaigns could promote earlier referrals and empower patients to seek necessary interventions. Early identification and treatment may also alleviate psychological distress linked to persistent pain and functional impairments, fostering better overall wellbeing.

The UniSA research elucidates a pressing need for systemic change in cancer care models. Embedding podiatry within multidisciplinary oncology teams, alongside oncologists, nurses, and physiotherapists, could holistically address the complex challenges posed by CIPN. Such collaboration would facilitate integrated pathways where referrals are streamlined, and patients receive timely, personalized care to manage neuropathic symptoms effectively.

In conclusion, Chemotherapy-Induced Peripheral Neuropathy remains a significant yet underrecognized adverse effect of cancer treatment, profoundly impacting lower limb function and patient quality of life. The University of South Australia’s study casts a spotlight on an alarming service gap where many patients miss critical podiatric support that could mitigate CIPN’s damaging effects. Addressing this involves not only clinical guideline revisions and health system reforms but also an urgent cultural shift within oncology care paradigms. By repositioning podiatry at the forefront of CIPN management, healthcare providers can enhance survivorship outcomes and ensure that cancer treatment’s triumph is not overshadowed by preventable complications.

Subject of Research: Not applicable

Article Title: Patterns and Factors Associated with Podiatry Service Use Among Colorectal Cancer Patients Following Chemotherapy in South Australia: Focus on Chemotherapy-Induced Peripheral Neuropathy (CIPN)

News Publication Date: 3-Oct-2025

Web References: http://dx.doi.org/10.2147/JMDH.S552589

References: The authors declare there are no competing or conflicts of interest in this work.

Keywords: Cancer treatments, Chemotherapy, Side effects, Medical treatments

The research, a pooled analysis of two rigorous clinical trials conducted under controlled settings, enrolled chemotherapy-naïve patients at least 20 years of age who were scheduled to receive their first course of carboplatin-containing chemotherapy for solid tumors. This comprehensive approach ensures that findings are robust and reflective of a real-world scenario, where nausea management can profoundly impact patient outcomes. The studies included a single-arm phase II trial and a randomized, double-blind, placebo-controlled phase III trial with very similar inclusion criteria and therapeutic regimens.

Patients in the experimental group received olanzapine at a dose of 5 mg daily, administered after dinner from day one through day four post-chemotherapy. This was in combination with a neurokinin-1 (NK1) receptor antagonist aprepitant, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, and dexamethasone, creating a multifaceted antiemetic cocktail designed to target different pathways responsible for inducing nausea and vomiting. The control group received a placebo alongside the standard triple antiemetic therapy, ensuring the study’s findings could be attributed directly to the addition of olanzapine.

The primary endpoint centered on the proportion of patients who remained free from nausea throughout the overall assessment period spanning the first 120 hours post-chemotherapy. This time frame captures both the acute and delayed phases of CINV, which are critical to patient comfort and treatment compliance. Statistical analysis included intergroup comparisons with 95% confidence intervals to delineate the efficacy of olanzapine-enhanced therapy compared to placebo.

Results revealed a striking improvement in the control of nausea among patients receiving olanzapine. Approximately 87.5% of olanzapine-treated patients reported being free from nausea, a significant leap compared to 75.0% without olanzapine. This 12.5% absolute increase in nausea-free patients underscores olanzapine’s pivotal role in enhancing antiemetic effectiveness in the carboplatin setting. Furthermore, appetite loss, a common secondary concern correlating with nausea, was also better managed in the olanzapine cohort, with a difference in appetite preservation of over 20% relative to placebo.

Beyond nausea control, the olanzapine group showed higher overall complete response rates—defined as no vomiting episodes and no need for rescue medications—at 88%, compared with 80.6% for those receiving placebo. This finding is remarkable because it illustrates not only reduction in subjective nausea sensation but also a tangible decrease in vomiting events, which have more severe physiological consequences. Olanzapine’s multifactorial receptor blockade, impacting dopaminergic, serotonergic, and histaminergic pathways, likely underpins this superior control.

A multivariable logistic regression analysis highlighted the absence of olanzapine use as a significant predictor of nausea occurrence, confirming the drug’s independent beneficial effect. Other patient-related factors—such as age, sex, and cancer type—were less predictive in comparison, emphasizing olanzapine’s contribution when added to a well-established antiemetic regimen. This evidence points towards olanzapine becoming a standard adjunctive therapy for carboplatin-induced CINV.

The implications of these findings are profound. Clinicians have long grappled with the challenge of managing delayed-phase nausea, which has proven resistant to conventional therapies. The integration of olanzapine promises to reshape current prophylactic strategies, potentially reducing the overall clinical burden of CINV and improving patient adherence to essential chemotherapy schedules. Importantly, olanzapine’s dosage of 5 mg appears both efficacious and tolerable, balancing symptom control with minimal adverse effects.

Moreover, this pooled analysis bridges data across trial designs and patient populations, validating the reproducibility of olanzapine’s benefits. It also underscores the importance of multimodal approaches attacking nausea pathways from different angles—NK1 receptor antagonism, serotonin-3 receptor blockade, corticosteroid anti-inflammatory action, and dopamine receptor antagonism through olanzapine. Such comprehensive intervention is key to overcoming nausea’s multifactorial pathophysiology.

These results pave the way for further investigation into olanzapine’s role across other chemotherapy agents beyond carboplatin, many of which also induce significant nausea. Additionally, future research may explore the optimal timing, dosing, and duration of olanzapine administration to maximize therapeutic outcomes. Patient-reported outcomes, quality of life metrics, and cost-effectiveness analyses will be crucial in defining olanzapine’s place in routine oncologic care.

It is also worth considering the biological mechanisms by which olanzapine exerts its antiemetic effect. Its antagonism of multiple receptors involved in nausea signaling highlights why it might outperform single-target agents. Its interaction with the central nervous system’s emesis control centers may dampen the cascade of neurotransmitters that trigger nausea and vomiting, providing patients with longer-lasting relief throughout the challenging chemotherapy cycle.

As healthcare moves towards more personalized and precision medicine strategies, identifying patients most likely to benefit from olanzapine-based regimens will be vital. This could include evaluating genetic predispositions, metabolic profiles, or cancer-specific nausea risks. Integration of such tailored approaches would maximize efficacy while minimizing unnecessary medication burden.

In conclusion, the landmark analysis reported in BMC Cancer represents a significant step forward in supportive cancer care. The combination of olanzapine with a triple antiemetic regimen demonstrably improves control of carboplatin-induced nausea and vomiting, mitigating two of the most distressing chemotherapy side effects and enhancing patient quality of life. This advancement exemplifies how thoughtful drug repurposing and rigorous clinical investigations can transform symptom management paradigms.

As the oncology community embraces these findings, the hope is that more patients will complete their intended chemotherapy cycles without the debilitating setbacks of nausea. The results also encourage wider adoption of olanzapine in antiemetic protocols globally, signaling a new era in comprehensive nausea prevention. The persistent problem of CINV might finally be meeting a resilient opponent in olanzapine, offering cancer patients renewed comfort and confidence during treatment.

This pivotal discovery not only underscores the importance of continuous research but also empowers clinicians and patients alike with enhanced tools for combating the burdens of cancer therapy. By directly addressing nausea with scientifically validated therapies, cancer care transitions one step closer to truly holistic treatment experiences, where survival and quality of life advance hand in hand.

Subject of Research: Prevention and control of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing carboplatin-containing chemotherapy.

Article Title: Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials.

Article References:
Kojima, S., Inui, N., Suzuki, T. et al. Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. BMC Cancer 25, 1494 (2025). https://doi.org/10.1186/s12885-025-14985-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14985-1

Pain in cancer patients manifests through complex mechanisms involving tumor infiltration, nerve compression, treatment side effects, and systemic inflammatory responses. Despite its multifactorial nature, effective pain alleviation is essential for optimal patient outcomes. However, in many low- and middle-income countries like Tanzania, systemic barriers often hinder the delivery of adequate pain control. These barriers range from limited access to opioid analgesics to fragmented healthcare infrastructure, compounded by socioeconomic and cultural factors that can influence treatment uptake and patient reporting of pain intensity.

The recent analytical cross-sectional study, carried out between October and December 2021, engaged 332 advanced cancer patients with solid tumors from two prominent health centers in Dar es Salaam: Aga Khan Hospital and Ocean Road Cancer Institute. By employing the Brief Pain Inventory Short Form (BPI-SF) alongside structured interviews to explore demographic and psychosocial variables, the researchers aimed to quantify the adequacy of pain management and identify significant predictive factors impacting patient outcomes. The utilization of the BPI-SF, a validated clinical tool, enhances the reliability of pain assessment, capturing both the intensity of pain and the extent to which it interferes with daily functioning.

Statistical analyses, including chi-square tests and logistic regression models executed via SPSS software version 25, provided a robust framework for unraveling correlations between patient characteristics and pain management efficacy. Results revealed that approximately 60% of participants reported adequate pain control, a figure that underscores both progress and the pressing need for improvement. These findings are notable within the Tanzanian context, given the resource limitations and challenges in widespread availability and administration of analgesics, especially strong opioids.

A crucial dimension uncovered by the study is the influence of sociodemographic factors on pain relief adequacy. Females were found nearly twice as likely to experience effective pain management compared to males, indicating potential gender-related differences in healthcare engagement, pain reporting, or provider biases. Moreover, educational attainment emerged as a significant determinant, with individuals possessing primary education exhibiting higher odds of receiving adequate pain control relative to those with nonformal education, suggesting that even foundational literacy might facilitate better communication with healthcare providers or adherence to pain management regimens.

Employment status further stratified outcomes in an impactful manner. Patients employed in formal jobs were more likely to receive sufficient pain relief, while those who were self-employed or unemployed experienced considerably lower odds of adequate pain control. This disparity perhaps reflects economic and social vulnerabilities affecting healthcare access, affordability of medications, or prioritization by care teams. These findings draw attention to the deeply embedded intersections between socioeconomic status and health equity, emphasizing the need for policy interventions that address such disparities.

The study not only documents current realities but also prompts reflection on systemic inadequacies in palliative cancer care infrastructure. While Tanzania has witnessed a gradual expansion of palliative services, challenges such as inadequate healthcare provider training, limited opioid availability regulated by stringent policies, and cultural stigma surrounding pain medication may collectively compromise optimal care delivery. Addressing these structural barriers necessitates multi-level strategies encompassing regulatory reform, provider education, patient advocacy, and community engagement.

Furthermore, the research underscores the critical importance of personalized pain management approaches. Recognizing the diversity in patient demographics and socioeconomic backgrounds serves as a blueprint for tailoring interventions that transcend one-size-fits-all models. For instance, integrating psychosocial support, enhancing literacy on pain management, and ensuring consistent follow-up could significantly improve adherence to treatment and patient satisfaction.

Beyond Tanzania, the study’s implications ripple across similar low-resource environments grappling with the dual burdens of rising cancer incidence and underdeveloped palliative frameworks. It challenges global health stakeholders to recalibrate priorities, advocating for universal access to effective pain control as a fundamental human right within cancer care. The data serves as an empirical foundation to fuel advocacy for increased funding, streamlined opioid access, and multidisciplinary care integration.

Scientifically, this investigation highlights the utility of applying rigorous epidemiological and statistical methodologies in resource-limited settings to capture nuanced patterns in health outcomes. It sets a precedent for further longitudinal and interventional studies that can evaluate the effectiveness of implemented strategies aimed at improving pain management metrics and patient-reported quality of life.

Moreover, the study illuminates the role of cultural perceptions and patient-healthcare provider communication in shaping pain management experiences. In many African contexts, cultural norms may influence patients’ willingness to report pain or use certain medications, necessitating culturally sensitive education and counseling programs. Empowering patients with knowledge about pain physiology, available treatments, and the importance of symptom reporting can transform care pathways and reduce suffering.

In conclusion, the research from Dar es Salaam offers a vital lens through which the complexities of cancer pain management in low-resource settings can be understood and addressed. By elucidating the determinants of pain management adequacy, the study provides targeted insights for clinicians, policymakers, and global health advocates aiming to refine palliative cancer care. It calls for sustained commitment to bridging sociodemographic inequities, bolstering healthcare delivery systems, and fostering patient-centered care models that prioritize dignity and relief for those battling advanced cancer.

As the burden of cancer continues to escalate worldwide, especially in regions with fragmented health systems, studies like this underscore the imperative to embed pain management at the core of palliative services. The Tanzanian experience thus becomes a microcosm reflecting broader challenges and opportunities in oncology, inspiring a global endeavor toward ensuring that no cancer patient endures unmitigated pain.

Subject of Research: Adequacy of pain management among advanced cancer patients with solid tumors in palliative care settings

Article Title: Adequacy of pain management among advanced cancer patients with solid tumors attending palliative care centers in Dar es Salaam

Article References:
Mwijage, J., Kyejo, W., Rubagumya, D. et al. Adequacy of pain management among advanced cancer patients with solid tumors attending palliative care centers in Dar es Salaam. BMC Cancer 25, 949 (2025). https://doi.org/10.1186/s12885-025-14385-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14385-5